Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A CRX-positive RB1-deficient bone tumour with a retinoblastoma-like DNA methylation profile.

Histopathology·2026
Same author

MUC4-Positive Fibroblastoma: Clinicopathological and Molecular Analysis of 7 Cases.

The American journal of surgical pathology·2026
Same author

Ozonated Olive Oil Attenuates Hepatic Steatosis in Obese db/db Mice: Evidence for Triacylglycerol-derived Ozonides as Key Bioactive Species.

Journal of oleo science·2026
Same author

Comparing artificial intelligence and physician performance in predicting IDH mutation status in glioma.

NPJ digital medicine·2026
Same author

Radiomics-based preoperative survival prediction in newly diagnosed glioblastoma: A multicohort study with internal and external validation.

Neuro-oncology advances·2026
Same author

Durable tumor control with stereotactic radiotherapy and doxorubucin-ifosfamide chemotherapy in primary intracranial sarcoma, <i>DICER1</i>-mutant: a case report.

International cancer conference journal·2026

Related Experiment Video

Updated: Apr 27, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.0K

IDH1/2 mutation detection in gliomas.

Hideyuki Arita1, Yoshitaka Narita, Akihiko Yoshida

  • 1Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan, h-arita@nsurg.med.osaka-u.ac.jp.

Brain Tumor Pathology
|July 11, 2014
PubMed
Summary

Isocitrate dehydrogenase (IDH) mutations are key glioma markers. Accurate IDH1/2 testing is crucial, but methods vary, requiring careful selection based on lab needs and sample types.

More Related Videos

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.3K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

7.4K

Related Experiment Videos

Last Updated: Apr 27, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.0K
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.3K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

7.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Neuropathology

Background:

  • Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) are critical biomarkers in glioma.
  • IDH1/2 status influences glioma classification, genetic landscape, and clinical presentation.
  • Accurate and reliable IDH1/2 testing is essential for glioma diagnosis and management.

Purpose of the Study:

  • To review the clinical significance of IDH1/2 mutations in gliomas.
  • To provide an overview of current methods for IDH1/2 mutation testing.
  • To guide the selection of optimal testing strategies based on specific laboratory contexts.

Main Methods:

  • Literature review of studies on IDH1/2 mutations in gliomas.
  • Analysis of various molecular testing techniques for IDH1/2 mutations.
  • Evaluation of factors influencing the choice of testing methods.

Main Results:

  • IDH1/2 mutations are strongly correlated with specific glioma subtypes and molecular profiles.
  • Multiple methods exist for IDH1/2 testing, each with distinct advantages and limitations.
  • No single method is universally optimal; selection depends on factors like sample type and available resources.

Conclusions:

  • IDH1/2 mutation status is a pivotal diagnostic and prognostic marker in gliomas.
  • Understanding the nuances of different IDH1/2 testing methodologies is vital for accurate clinical application.
  • Tailoring the testing approach to laboratory capabilities and clinical needs ensures robust and reliable results.